Trinean nv to In-License PerkinElmer, Inc. Technology

Ghent, Belgium – February 4th, 2013 - Trinean, the leading provider of microfluidic spectrophotometry platforms, today announced that it has entered into a license agreement with PerkinElmer to license certain microfluidics technology owned by its subsidiary, Caliper Life Sciences, Inc., in the field of UV-VIS quantification analysis.

Under the agreement, Trinean obtained a license for the design and development of microfluidic cartridges and instruments in the field of UV/VIS quantification of light- absorbing substances for certain life sciences research applications.

“We are very pleased with this agreement between PerkinElmer and Trinean. The combined IP from Trinean and PerkinElmer will boost the expansion of our platform for DNA, RNA and protein quantification and quality control," said Philippe Stas, CEO of Trinean. "Our microfluidic chips generate high quality UV/Vis spectral absorbance profiles of bio-molecules. They are designed to meet the requirements of labs requiring speed and minimal sample usage. Our unmatched large measurement range allows quantification of undiluted protein samples in real-time thereby significantly shortening the purification process.”

"The use of microfluidics for UV/Vis spectrometry is an exciting market development," said Kevin Hrusovsky, Life Sciences President, PerkinElmer. "We continue to leverage our microfluidics portfolio through licensing collaborations such as our agreement with Trinean to extend our market reach and create additional revenue opportunities."

More information about PerkinElmer’s microfluidics portfolio can be found at: http://www.perkinelmer.com/catalog/category/id/labchip%20systems

About Trinean

Trinean is a Belgium based instrumentation company, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform.

Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes two instruments, the Xpose for Touch & Go biomolecule quantification and the DropSense96®, analyzing up to 96 samples, using microfluidic chips for standardized sample analysis (DropPlates and Xpose Slides). The Trinean platform is complemented with a software toolbox (including DropControl, DropQuant, cDrop™) for improved data interpretation and lab-automation. For more information about Trinean, visit http://www.trinean.com

Further information:

Trinean N.V.

ir. Philippe Stas

Chief Executive Officer

Dulle Grietlaan 17/3

B-9050 Gent – Belgium

Tel.: +32-9-272.75.35

Fax.: +32-9-272.75.39

info@trinean.com